By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide
[DOI] [PMC free article] [PubMed] [Google Scholar] 526.Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C
Consistently using the same spot can lead to skin irritation, scarring, or hard lumps under the skin
But with such a large volume of GLP-1 drugs moving through the system so quickly, the FDA may not have the time or resources to inspect in as much detail, Moore says
Anticonceptivos hormonales orales : La FDA recomienda usar mtodos anticonceptivos no orales o aadir un mtodo de barrera durante 4 semanas despus del inicio del tratamiento y durante 4 semanas despus de cada aumento de dosis